- CBD inhibits CYP3A4 and CYP2C9 — two liver enzymes that collectively metabolize an estimated 60–70% of all prescription medications, including warfarin, statins, seizure drugs, and many more.
- The interaction mechanism is identical to grapefruit juice: both inhibit CYP3A4 in the intestinal wall and liver. Any medication with a grapefruit warning should be treated with the same caution around CBD.
- CBD approximately doubles blood levels of the seizure medication clobazam in documented clinical cases — this interaction was confirmed during Epidiolex (pharmaceutical CBD) clinical trials.
- Warfarin users who consume cannabis can experience significant INR elevation and increased bleeding risk; multiple published case reports document hemorrhagic events.
- THC produces additive CNS depression when combined with opioids, benzodiazepines, alcohol, or sedative-hypnotics — a combination that can cause life-threatening respiratory depression.
- High-THC cannabis combined with stimulants (amphetamines, cocaine) can produce severe anxiety, tachycardia, and in rare cases, acute cardiovascular events.
- A clinical pharmacist consultation is the most reliable way to assess interaction risk before beginning cannabis with a complex medication regimen.
The CYP450 Enzyme System: Why It Controls Most Drug Interactions
To understand cannabis drug interactions, you first need to understand how the liver processes pharmaceuticals. The cytochrome P450 (CYP450) enzyme family is a superfamily of metabolic enzymes located primarily in the liver and the intestinal wall. Their job is to break down foreign compounds — including drugs, plant chemicals, environmental toxins, and cannabis cannabinoids — into forms that can be safely excreted. This metabolic process is called drug biotransformation or Phase I metabolism.
The problem with drug interactions arises when one compound modifies the activity of a CYP enzyme in a way that affects the metabolism of another compound processed by the same enzyme. If Compound A inhibits CYP3A4, and Compound B is normally metabolized and cleared by CYP3A4, then when A and B are taken together, B is not cleared as efficiently. B accumulates in the bloodstream to higher concentrations than intended by the prescriber who set the dose assuming normal CYP3A4 activity. The result: B produces stronger effects, potentially including toxic effects, even at its standard dose.
This is the essential mechanism of most significant cannabis-drug interactions. CBD (cannabidiol) is a potent inhibitor of both CYP3A4 (which metabolizes approximately 50% of all pharmaceuticals) and CYP2C9 (which metabolizes approximately 15% of pharmaceuticals, including warfarin). THC also inhibits some CYP enzymes but is considered a weaker inhibitor than CBD at typical therapeutic concentrations. Together, cannabis consumption — especially high-dose oral CBD — can significantly alter the pharmacokinetics of dozens of concurrent medications. Our companion guide on cannabis for seniors covers the specific implications for older adults on polypharmacy regimens.
The Grapefruit Warning: A Familiar Analogy
Many people are surprised to learn that grapefruit juice has been a documented drug interaction concern for decades. Grapefruit contains furanocoumarins (particularly bergamottin and 6’,7’-dihydroxybergamottin) that irreversibly inhibit CYP3A4 in the intestinal wall. This creates an interaction with the same class of drugs that CBD affects. The grapefruit warning appears on the packaging of statins (particularly simvastatin and atorvastatin), certain calcium channel blockers, immunosuppressants, and many other medications precisely because of CYP3A4 inhibition.
CBD’s mechanism of CYP3A4 inhibition is competitive rather than irreversible (unlike grapefruit), but the practical result is similar: drugs that depend on CYP3A4 for clearance are cleared more slowly in the presence of CBD, accumulating to higher blood concentrations. A useful rule of thumb: if your medication has a grapefruit interaction warning, treat CBD with the same level of caution and discuss it with your prescribing physician or pharmacist before using cannabis.
High-Risk Drug Interaction Table
The following table summarizes the most clinically significant cannabis-drug interactions, organized by risk level. This is not exhaustive; many additional interactions exist. Consult a pharmacist for a comprehensive review of your specific medication list.
| Medication / Class | Cannabis Component | Mechanism | Risk / Effect | Risk Level |
|---|---|---|---|---|
| Warfarin (Coumadin) | CBD | CYP2C9 inhibition → warfarin accumulates | INR elevation, increased bleeding risk | HIGH |
| Clobazam (Onfi) | CBD | CBD inhibits CYP3A4/CYP2C19; N-desmethylclobazam doubles | Sedation, respiratory depression | HIGH |
| Valproate (Depakote) | CBD | Additive hepatotoxicity risk (liver enzyme elevation) | Liver enzyme elevations, hepatotoxicity | HIGH |
| Tacrolimus / cyclosporine | CBD | CYP3A4 inhibition; immunosuppressant levels rise | Nephrotoxicity, toxicity from drug accumulation | HIGH |
| Opioids (morphine, oxycodone) | THC + CBD | Additive CNS and respiratory depression | Over-sedation, respiratory depression risk | HIGH |
| Statins (simvastatin, atorvastatin) | CBD | CYP3A4 inhibition; statin levels rise | Myopathy, rhabdomyolysis risk | MODERATE |
| Benzodiazepines (diazepam, alprazolam) | THC + CBD | Additive CNS depression + CYP3A4 inhibition | Excessive sedation, fall risk, memory impairment | MODERATE |
| SSRIs (sertraline, fluoxetine) | CBD + THC | CYP2D6 inhibition; theoretical serotonergic interaction | Elevated SSRI levels; theoretical serotonin syndrome | MODERATE |
| Rifampicin (Rifampin) | THC + CBD | Rifampicin induces CYP enzymes → faster THC/CBD clearance | Reduced cannabis effect; reduced drug levels | LOW-MODERATE |
| Stimulants (Adderall, cocaine) | THC | Pharmacodynamic: synergistic cardiovascular stimulation | Tachycardia, anxiety, acute cardiovascular risk | MODERATE |
The Warfarin-Cannabis Interaction in Detail
Warfarin (brand name Coumadin) is one of the most widely prescribed anticoagulants in the world, used to prevent blood clots in conditions including atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is also one of the most interaction-prone drugs in clinical medicine, requiring careful monitoring of the International Normalized Ratio (INR) — a measure of how long blood takes to clot. Warfarin has a narrow therapeutic window: too little anticoagulation and clots form; too much and dangerous bleeding can occur.
Warfarin is primarily metabolized by CYP2C9. When CBD inhibits CYP2C9, warfarin clearance slows and plasma levels rise above the intended therapeutic concentration. The clinical result is INR elevation — meaning the blood takes longer to clot than intended. Multiple published case reports describe patients on stable warfarin anticoagulation who began using CBD oil and subsequently presented with elevated INR and in some cases with bleeding complications including bruising, nosebleeds, and more serious hemorrhagic events.
For patients on warfarin who want to use cannabis: this is not an absolute contraindication, but it requires physician involvement. Warfarin dosing would likely need to be adjusted downward, and INR monitoring would need to increase in frequency (possibly weekly rather than monthly). The same interaction applies to other CYP2C9-dependent anticoagulants and to some non-steroidal anti-inflammatory drugs (NSAIDs) that are also CYP2C9 substrates.
Clobazam: The Best-Documented CBD Interaction
The most rigorously documented cannabis-drug interaction in clinical medicine involves clobazam (Onfi), a benzodiazepine-type anticonvulsant used to treat Lennox-Gastaut syndrome and other refractory epilepsies. This interaction was studied prospectively during the clinical trials of Epidiolex (pharmaceutical-grade CBD), which is FDA-approved for Lennox-Gastaut and Dravet syndrome.
In the Epidiolex trials, patients receiving both CBD and clobazam showed dramatically increased blood levels of N-desmethylclobazam (the active metabolite of clobazam) compared to patients on clobazam alone. Levels approximately doubled, producing enhanced sedation and other side effects. The mechanism is CBD inhibition of CYP3A4 and CYP2C19, both of which are involved in clobazam metabolism. In clinical practice, when CBD is added to a clobazam regimen, the clobazam dose typically needs to be reduced and plasma levels monitored. This interaction is now well-established in epilepsy neurology and is managed routinely in clinical settings. For context on cannabis and epilepsy, see our medical cannabis for epilepsy guide.
Sedative Combinations: CNS Depression and Respiratory Risk
Cannabis — particularly at higher THC doses — produces dose-dependent central nervous system (CNS) depression: sedation, slowed reaction time, impaired coordination, and at very high doses, respiratory slowing. When combined with other CNS depressants, these effects are additive or potentially synergistic, creating risks that exceed what either substance would produce alone.
The most clinically concerning combination is high-dose THC with opioids. Opioids suppress the respiratory drive through activation of mu-opioid receptors in the brainstem; cannabis contributes additional CNS depression. While some research suggests that cannabis may allow some patients to reduce opioid doses for pain management (an “opioid-sparing” effect), combining high doses of both simultaneously creates respiratory depression risk. This is particularly relevant in the context of the opioid crisis, where fentanyl-contaminated illicit drug supplies make any CNS depressant combination potentially lethal.
Benzodiazepines + THC is another combination of concern, particularly in older adults. Both classes produce sedation and psychomotor impairment; combined, they significantly increase fall risk. CBD additionally inhibits CYP3A4, which is involved in clearing many benzodiazepines, potentially increasing benzodiazepine blood levels on top of the pharmacodynamic interaction. Alcohol is a CNS depressant that also impairs judgement, coordination, and judgement about how much of either substance to consume — compounding all risks when added to the mix.
Monitoring Parameters for Cannabis Users on Medication
If you use cannabis and take prescription medications, the following monitoring approach — in consultation with your physician or pharmacist — can help identify and manage interactions before they become clinically significant.
| Medication | What to Monitor | Frequency | Warning Signs |
|---|---|---|---|
| Warfarin | INR (prothrombin time) | Weekly initially; monthly when stable | Unusual bruising, prolonged bleeding, blood in urine |
| Clobazam / seizure meds | Plasma drug levels; seizure frequency | At initiation and dose change | Increased sedation, dizziness, more seizures |
| Statins | CK (creatine kinase), liver enzymes | At 3 months; then annually | Muscle weakness or pain, dark urine |
| Immunosuppressants | Drug trough levels, kidney function | More frequent when initiating | Signs of toxicity or rejection |
| Any CNS depressant | Sedation level, functional status | Ongoing self-assessment | Over-sedation, falls, respiratory changes |
The most valuable first step for anyone on multiple prescription medications who wants to begin using cannabis is a consultation with a clinical pharmacist. Pharmacists are specifically trained in drug interactions and can review your complete medication list against the cannabis interaction profile in a way that most physicians (who receive minimal pharmacology training beyond medical school) are not well-positioned to do. Many states with medical cannabis programs now have pharmacists in dispensaries who can provide this service.
WATCH: Cannabis Drug Interactions Explained